PRLD Short Volume
Prelude Therapeutics Incorporated (PRLD) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $259.7M, listed on NASDAQ, employing roughly 131 people, carrying a beta of 1.10 to the broader market. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. Led by Krishna Vaddi, public since 2020-09-25.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-05-15
- Short Volume
- 60.4K
- Total Volume
- 171.4K
- Short %
- 35.24%
- 30-Day Avg Short %
- 35.24%
Showing 30 days of FINRA short volume data for Prelude Therapeutics Incorporated.
Learn how short volume is reported and how to read the data →
Frequently asked PRLD short volume questions
- What is the daily PRLD short volume?
- As of May 15, 2026, Prelude Therapeutics Incorporated (PRLD) short volume is 60.4K shares against 171.4K total reported volume, or 35.24% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is PRLD short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does PRLD short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.